Table 1 Baseline and clinical characteristics of all CAEBV patients
Patient | Age at onset, years | Gender | Complication before HSCT | Stem cell source (donor, HLA identity) | Donor type | Time to HSCT, months | Disease status | EBV-infected cells | Preconditioning | Infused cells | |
|---|---|---|---|---|---|---|---|---|---|---|---|
MNC (108/kg) | CD34+ (106/kg) | ||||||||||
PTCy-1 | 15 | M | Herpes zoster | PB (father, 7/10) | Haplo | 87 | Active | NK | FLU/VP16/BU4/CY | 6.05 | 3.43 |
PTCy-2 | 4 | F | None | PB (father, 7/10) | Haplo | 4 | Non-active | T | FLU/VP16/BU4/CY | 7 | 10 |
PTCy-3 | 4 | M | Sepsis, lung infection | PB (father, 5/10) | Haplo | 16 | Active | T/NK | FLU/VP16/BU4/CY | 17.05 | 17.67 |
PTCy-4 | 2 | M | Virus pneumonia; central invaded | PB (father, 5/10) | Haplo | 5 | Non-active | T/NK | FLU/VP16/BU4/CY | 14 | 8 |
PTCy-6 | 3 | F | Pancreatitis; enlarged coronary artery | PB (father, 5/10) | Haplo | 6 | Active | T/NK | FLU/VP16/BU4/CY | 10 | 7.46 |
PTCy-7 | 6 | F | Myocardial damage, cardiomegaly | PB (mother, 5/10) | Haplo | 37 | Active | T/NK | FLU/VP16/BU4/CY | 16.8 | 6.9 |
PTCy-8 | 6 | F | Papular rash | PB (father, 7/10) | Haplo | 7 | Non-active | T/NK | FLU/VP16/BU4/CY | 10 | 8 |
PTCy-9 | 5 | F | Rash | PB (mother, 5/10) | Haplo | 6 | Non-active | NK | FLU/VP16/BU4/CY | 10 | 6.8 |